// App-Quantinova.ai

: Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.

Researchers

Presenter

  • Rohit K. Jain

Principal Investigators

  • Yuanquan Yang

  • Juskaran Chadha

  • Monica Sheila Chatwal

  • Julie Ann Kish

  • Sarah Raymond

  • Jennifer Rembisz

  • Ghazal Jameel

  • Arfa Mustasam

  • Trey Poehlman

  • Wenyi Fan

  • Youngchul Kim

  • Jasreman Dhillon

  • Carlos A. Alemany

  • Amir Mortazavi

  • Jingsong Zhang

  • Guru P. Sonpavde

Medical Centers

  • AdventHealth Cancer Institute, Orlando, FL

  • Moffitt Cancer Center, Tampa, FL

  • Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

  • H. Lee Moffitt Cancer Center & Research Institute, Riverview, FL

  • The Ohio State University Comprehensive Cancer Center, Division of Radiation Oncology, Columbus, OH

  • The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital, Richard J. Solove Research Institute, Columbus, OH

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • N/A

Drug/Treatment

  • IMMU132

  • Ipilimumab

  • Cisplatin

  • Nivolumab

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • I/II

Study Id's

  • NCT04863885

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved